Expert Review of Anti-infective Therapy最新文献_第2页

Neurotoxicity risk associated with cefepime versus piperacillin-tazobactam in hospitalized patients with pneumonia: a real-world cohort study. 头孢吡肟与哌拉西林-他唑巴坦对住院肺炎患者的神经毒性风险相关：一项真实世界队列研究。

IF 4.6 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2026-10-01 Epub Date: 2026-07-16 DOI: 10.1080/14787210.2026.2703097

Yu-Ju Tseng, Hui-Lin Yu, Chi-Chuan Wang, Kuo-Chuan Wang, Chien-Chih Wu

{"title":"Neurotoxicity risk associated with cefepime versus piperacillin-tazobactam in hospitalized patients with pneumonia: a real-world cohort study.","authors":"Yu-Ju Tseng, Hui-Lin Yu, Chi-Chuan Wang, Kuo-Chuan Wang, Chien-Chih Wu","doi":"10.1080/14787210.2026.2703097","DOIUrl":"10.1080/14787210.2026.2703097","url":null,"abstract":"Background: Cefepime (FEP) and piperacillin-tazobactam (TZP) are antipseudomonal β-lactams widely prescribed for pneumonia. Although FEP-associated neurotoxicity is increasingly recognized, comparative safety data remain limited, particularly outside critical care settings.Research design and methods: This single-center retrospective cohort study included adults with pneumonia who received empirical intravenous FEP or TZP at National Taiwan University Hospital (2016-2019). Patients receiving concurrent neurotoxic agents or antibiotic therapy <48 hours were excluded. The primary outcome was antibiotic-associated neurotoxicity, adjudicated by two pharmacists using the Naranjo scale (score ≥5). Firth's penalized likelihood logistic regression examined the antibiotic-neurotoxicity association.Results: Among 842 patients (FEP, 137; TZP, 705), neurotoxicity occurred in 5 (3.7%) FEP-treated and 1 (0.1%) TZP-treated patients (p = 0.0006). In an exploratory, unadjusted analysis, FEP exposure was associated with neurotoxicity (OR 19.50, 95% CI 3.17-120.01; p = 0.0014). However, the wide confidence interval and likely under-ascertainment of the outcome - delirium and the highest-risk patients were excluded - render these estimates exploratory.Conclusions: FEP may be associated with a higher neurotoxicity risk than TZP in hospitalized patients with pneumonia; however, given the single-center design and very small number of events, these findings should be regarded as exploratory and hypothesis-generating rather than confirmatory.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"991-999"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148419757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leveraging pharmacokinetic and pharmacodynamic relationships to prevent the emergence of antimicrobial resistance. 利用药代动力学和药效学关系来预防抗菌素耐药性的出现。

IF 4.6 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2026-10-01 Epub Date: 2026-07-19 DOI: 10.1080/14787210.2026.2705572

Abrar K Thabit, Alaa F Alsehemi, Raneem F Masoud

引用次数: 0

Pharmacokinetic considerations of commonly administered antimicrobial agents in hematopoietic stem cell transplant patients. 造血干细胞移植患者常用抗菌药物的药代动力学考虑。

IF 4.6 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2026-10-01 Epub Date: 2026-07-22 DOI: 10.1080/14787210.2026.2706021

Parisa Ghasemiyeh, Elahehnaz Parhizkar, Soliman Mohammadi-Samani

{"title":"Pharmacokinetic considerations of commonly administered antimicrobial agents in hematopoietic stem cell transplant patients.","authors":"Parisa Ghasemiyeh, Elahehnaz Parhizkar, Soliman Mohammadi-Samani","doi":"10.1080/14787210.2026.2706021","DOIUrl":"10.1080/14787210.2026.2706021","url":null,"abstract":"Introduction: Hematopoietic stem cell transplantation (HSCT) is considered the treatment of choice for various malignant and nonmalignant hematologic disorders. HSCT patients are commonly subject to polypharmacy and receive multiple therapeutic regimens during the pre-, peri-, and post-transplantation periods. Administration of various antimicrobial agents as prophylactic or therapeutic regimens is essential in HSCT patients.Areas covered: This comprehensive review focuses mainly on the pharmacokinetic (PK) aspects and therapeutic drug monitoring (TDM) of commonly administered antimicrobial agents, including antibacterial, antiviral, and antifungal agents in HSCT patients. Additionally, alterations in PK parameters and specific recommendations for TDM are discussed in detail.Expert opinion: Since HSCT patients often have altered PK characteristics and require multiple concomitant medications, individualized dosing based on their PK and pharmacogenetic profiles is crucial. Close monitoring of potential drug-drug interactions (PDDIs) and plasma concentrations is essential to achieve an optimal clinical response, minimize drug-related toxicities, and improve post-transplant survival. In general, many of the commonly administered antibiotics in HSCT patients showed increased volume of distribution and clearance, decreased half-lives, and therefore decreased area under the curve (AUC) values compared to the normal population. Therefore, higher doses of these antibiotics should be administered along with close patient monitoring and assessment of plasma concentrations.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"927-944"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148469929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current overview of health technologies for antimicrobial resistance (AMR) management in hospitals: a scoping review, bibliometric analysis and technological prospecting. 医院抗菌素耐药性（AMR）管理卫生技术现状综述：范围综述、文献计量学分析和技术展望。

IF 4.6 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2026-10-01 Epub Date: 2026-07-22 DOI: 10.1080/14787210.2026.2707342

Rafael Martins Dos Santos, Alice Ribeiro de Souza Menezes, Kátia Cristiane Hall, Leandro Farias Rodrigues, Andressa da Silva Barboza, Carla Lucía David Peña, Rafael Guerra Lund

{"title":"Current overview of health technologies for antimicrobial resistance (AMR) management in hospitals: a scoping review, bibliometric analysis and technological prospecting.","authors":"Rafael Martins Dos Santos, Alice Ribeiro de Souza Menezes, Kátia Cristiane Hall, Leandro Farias Rodrigues, Andressa da Silva Barboza, Carla Lucía David Peña, Rafael Guerra Lund","doi":"10.1080/14787210.2026.2707342","DOIUrl":"10.1080/14787210.2026.2707342","url":null,"abstract":"Introduction: Antimicrobial resistance (AMR) represents one of the greatest global public health challenges and is intensified by inappropriate antimicrobial use, mobility, and limited availability of novel therapeutic options. Digital health technologies have emerged as strategies to improve surveillance, prevention, clinical decision-making, and antimicrobial stewardship in hospital settings.Areas covered: This study mapped health technologies applied to AMR management through a scoping review combined with bibliometric analysis and technological prospecting. The review followed PRISMA-ScR guidance and included peer-reviewed studies published between 2000 and 2025. The approach identified not only implemented digital interventions but also publication trends, collaboration networks, and patent-stage innovation. Clinical decision-support systems, electronic surveillance platforms, and artificial intelligence applications were the most reported technologies, while patent analysis revealed innovations concentrated in diagnostics, predictive analytics, automated monitoring, and precision antimicrobial management.Expert opinion/commentary: Digital technologies are becoming important components of AMR management; however, the evidence remains heterogeneous and mostly descriptive. Key barriers include limited interoperability, unequal infrastructure, insufficient real-world clinical validation, data governance concerns, and restricted implementation beyond hospital environments. Future research should prioritize validated, explainable, interoperable, and scalable digital ecosystems, with One Health integration considered a direction rather than a conclusion directly demonstrated by the hospital-based evidence mapped here.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"945-963"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148520350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genomic characterization of Gram-negative bacteria isolated from conflict-trauma patients in a southern Lebanese hospital. 从黎巴嫩南部一家医院的冲突创伤患者中分离出的革兰氏阴性细菌的基因组特征

IF 4.6 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2026-10-01 Epub Date: 2026-08-19 DOI: 10.1080/14787210.2026.2713858

Anwar Al Souheil, Hadi Hussein, Dayana Shoukair, Abdallah Kurdi, Karim Allaw, Mohamad Ghassan Abiad, Hassan Jamil Kazma, Rana El Hajj, Mahmoud I Khalil, Souha S Kanj, Ghassan M Matar, Paul G Higgins, Louis-Patrick Haraoui, Antoine Abou Fayad

{"title":"Genomic characterization of Gram-negative bacteria isolated from conflict-trauma patients in a southern Lebanese hospital.","authors":"Anwar Al Souheil, Hadi Hussein, Dayana Shoukair, Abdallah Kurdi, Karim Allaw, Mohamad Ghassan Abiad, Hassan Jamil Kazma, Rana El Hajj, Mahmoud I Khalil, Souha S Kanj, Ghassan M Matar, Paul G Higgins, Louis-Patrick Haraoui, Antoine Abou Fayad","doi":"10.1080/14787210.2026.2713858","DOIUrl":"10.1080/14787210.2026.2713858","url":null,"abstract":"Introduction: Conflict-related injuries create a unique environment for the emergence of antimicrobial-resistant pathogens.Methods: To clarify the burden and dynamics of resistance in this high-risk population, we investigated the genomic and clinical profiles of 63 Gram-negative bacterial isolates recovered exclusively from conflict-trauma cases in Southern Lebanon during the 2024 war.Results: Whole-genome sequencing revealed Acinetobacter baumannii (31.7%) and Escherichia coli (20.6%) as the predominant species, marking a significant epidemiological shift toward A. baumannii compared to pre-conflict baselines. Acquired antimicrobial resistance genes were detected in 66.7% of isolates, with a high prevalence of determinants and mutations targeting aminoglycosides (87%), fluoroquinolones (74.6%), and carbapenems (54%). Carbapenem resistance was primarily driven by acquired blaOXA carbapenemases and blaNDM variants; notably, we report the first detection of blaNDM-40 in Lebanon, alongside blaNDM-1 and blaNDM-5. Minimum spanning tree analysis highlighted clonal, healthcare-associated transmission for A. baumannii and Klebsiella pneumoniae, contrasted by polyclonal distributions for E. coli and Pseudomonas aeruginosa.Conclusion: Extensive broad-spectrum antibiotic exposure and acute trauma care within compromised healthcare infrastructures accelerate the selection of multidrug-resistant (MDR) genotypes. Mitigating this dissemination in conflict settings requires integrating genomic surveillance with targeted antimicrobial stewardship and infection control.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"981-990"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is fluoroquinolone use controversial? 氟喹诺酮类药物的使用有争议吗？

IF 4.6 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2026-09-29 DOI: 10.1080/14787210.2026.2740110

Joseph M Blondeau, Glenn S Tillotson

引用次数: 0

Zika virus in the Americas: transmission dynamics, clinical lessons, and future risk. 美洲寨卡病毒：传播动态、临床教训和未来风险

IF 4.6 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2026-09-29 DOI: 10.1080/14787210.2026.2741271

Natalia Guimaraes, Talita Adelino, Luiz Carlos Junior Alcantara, Ana Maria Bispo de Filippis, José Lourenço, Marta Giovanetti

{"title":"Zika virus in the Americas: transmission dynamics, clinical lessons, and future risk.","authors":"Natalia Guimaraes, Talita Adelino, Luiz Carlos Junior Alcantara, Ana Maria Bispo de Filippis, José Lourenço, Marta Giovanetti","doi":"10.1080/14787210.2026.2741271","DOIUrl":"10.1080/14787210.2026.2741271","url":null,"abstract":"Introduction: The emergence of Zika virus (ZIKV) in the Americas in 2015-2016 transformed a neglected arbovirus into a major public health concern, revealing severe congenital and neurological complications and important weaknesses in surveillance and response. Although epidemic transmission has declined, low-level circulation persists and the risk of resurgence remains uncertain.Areas covered: This review synthesizes current evidence on ZIKV epidemiology, transmission dynamics, molecular evolution, and clinical impact in the Americas. We summarize findings from clinical, epidemiological, and genomic studies, highlighting how phylogenetic and phylogeographic analyses have reconstructed viral spread, revealed cryptic transmission before outbreak recognition, and clarified the roles of human mobility, vector ecology, and population immunity. Persistent diagnostic and surveillance challenges are also discussed.Expert opinion: Continued low-level circulation and major surveillance gaps indicate that ZIKV resurgence cannot be excluded. Integrated genomic, entomological, epidemiological, and clinical surveillance will be essential for early detection of transmission changes and more timely public health responses. Strengthening these systems will also improve preparedness for other emerging and re-emerging arboviruses.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-11"},"PeriodicalIF":4.6,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical use of dalbavancin in Canada: the CLEAR study final results. dalbavancin在加拿大的临床应用：明确的研究最终结果。

IF 4.6 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2026-09-29 DOI: 10.1080/14787210.2026.2740112

George G Zhanel, Michael Silverman, Janhavi Bhalla, Melanie Baxter, Reza Rahimi, Maggie Wong, Yazdan Mirzanejad, Timothy MacLaggan, Kiarah Shchepanik, Heather Wise, Neal Irfan, Gabriel Girouard, Rita Dhami, Melissa Kucey, Vida Stankus, Kristin Schmidt, Sébastien Poulin, William Connors, Zain Chagla, Alex Serebryanskyy, Carlo Tascini, Jean-François Tessier, Yoav Keynan, Andrew Walkty, James A Karlowsky

{"title":"Clinical use of dalbavancin in Canada: the CLEAR study final results.","authors":"George G Zhanel, Michael Silverman, Janhavi Bhalla, Melanie Baxter, Reza Rahimi, Maggie Wong, Yazdan Mirzanejad, Timothy MacLaggan, Kiarah Shchepanik, Heather Wise, Neal Irfan, Gabriel Girouard, Rita Dhami, Melissa Kucey, Vida Stankus, Kristin Schmidt, Sébastien Poulin, William Connors, Zain Chagla, Alex Serebryanskyy, Carlo Tascini, Jean-François Tessier, Yoav Keynan, Andrew Walkty, James A Karlowsky","doi":"10.1080/14787210.2026.2740112","DOIUrl":"10.1080/14787210.2026.2740112","url":null,"abstract":"Background: The CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry collected data on 160 Canadian patients who received dalbavancin between January 2023 and December 2025.Research design and methods: Clinicians used the web-based research data management program REDCapTM to enter patient information into the CLEAR registry.Results: Dalbavancin was most frequently prescribed for acute bacterial skin and skin structure infections (55.6% of patients) and bone/joint infections (24.4%). Methicillin-resistant Staphylococcus aureus (MRSA) (55.6%) and methicillin-susceptible S. aureus (MSSA) (14.4%) were the most common pathogens treated. Dalbavancin treatment was most frequently initiated on a hospital ward (55.0%) or in the emergency department (26.9%). Dalbavancin therapy was chosen because it was a single-dose treatment (71.4%) or facilitated hospital discharge (16.9%) and was primarily administered without other antimicrobial agents (83.1%) as a single 1500 mg dose (63.0%). Microbiological success (pathogen eradicated/presumed eradicated) and clinical success (cure and/or improvement) rates were 93.8% (106/113) and 86.4% (89/103), respectively, for patients with known outcomes. One adverse event (hypersensitivity) was reported.Conclusions: Dalbavancin has established itself as a unique and useful antimicrobial in Canada. CLEAR registry data confirm previously published peer-reviewed studies describing the efficacy and safety of dalbavancin in the treatment of various infections.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":4.6,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149037489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Measles resurgence in Europe: a public health setback. 欧洲麻疹死灰复燃：公共卫生倒退。

IF 4.6 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2026-09-28 DOI: 10.1080/14787210.2026.2740115

Maria Antonia De Francesco, Eugenia Quiros-Roldan

引用次数: 0

Emerging therapies for Candidozyma auris (Candida auris): current landscape and future directions. 耳念珠菌（Candida auris）的新疗法：现状和未来方向。

IF 4.6 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2026-09-28 DOI: 10.1080/14787210.2026.2740114

Liyang Zhang, Lewis Oscar Felix, Eleftherios Mylonakis

{"title":"Emerging therapies for Candidozyma auris (Candida auris): current landscape and future directions.","authors":"Liyang Zhang, Lewis Oscar Felix, Eleftherios Mylonakis","doi":"10.1080/14787210.2026.2740114","DOIUrl":"10.1080/14787210.2026.2740114","url":null,"abstract":"Introduction: The multidrug-resistant fungal pathogen Candidozyma auris (Candida auris) has spread rapidly across healthcare systems worldwide, emerging as a critical threat to patient safety. With a limited antifungal armamentarium increasingly compromised by rising resistance, the development of novel therapeutic strategies is urgently needed.Areas covered: This review examines emerging therapies for C. auris, organized by clinical maturity and molecular target, evaluates their discovery pipelines, and outlines the limitations. We also discuss combination therapies and decolonization strategies as approaches for preventing and treating C. auris infections.Expert opinion: C. auris continues to outpace the currently available therapeutic arsenal. The greatest near-term advances are likely to come from agents with novel mechanisms of action and from rational combination strategies. However, major translational barriers remain, including limited fungal-specific targets, pharmacokinetic challenges, and the gap between preclinical findings and clinical application. Progress will depend on integrating artificial intelligence-driven drug discovery, rational target selection, and optimized pharmacokinetic modeling to accelerate therapeutic development. Equally important is the development of effective decolonization strategies to interrupt healthcare transmission. Together, these advances could redefine C. auris treatment and address one of the most pressing challenges in contemporary medical mycology.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-13"},"PeriodicalIF":4.6,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149059422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0